Sustainability Report

Overview

The report highlights Imexpharm's 2025 growth, with gross revenue up 16.0% year-on-year and net revenue reaching VND 2,441.1 billion. The company launched 25 new products and maintained 157 R&D projects, including Vietnam's first EU-GMP first-generic antibiotic. It reports 2025 Scope 1 emissions of 1,198 tCO2e and Scope 2 emissions of 11,945 tCO2e, alongside energy savings and rooftop solar generation. The report also describes workforce, community, and governance initiatives.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services